MDRX, US01988P1084

Analysts set USD 8.00 target for Veradigm stock

Published on 10/05/2026 at 19:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Veradigm estimates 2025 revenue at USD 584 million to USD 589 million. Analysts set a USD 8.00 target for Veradigm stock.

MDRX, US01988P1084, Illustration mit AI erstellt.

Analysts set a USD 8.00 target for Veradigm stock, while the company presented a transformation strategy at two healthcare conferences on September 15 and September 16, 2026. As The Globe and Mail reported on October 2, 2026, the latest cited analyst rating was Buy with a USD 8.00 target.

Revenue estimate sets the scale

The investor presentation estimated 2025 revenue at USD 584 million to USD 589 million. That range gives the restructuring plan a measurable operating base as management moves from filing recovery toward renewed growth.

TradingView reported on September 15, 2026, that Veradigm disclosed the USD 584 million to USD 589 million 2025 revenue estimate and a plan to seek relisting after bringing its SEC filings current.

Balance sheet and filings matter

The same presentation put year-end 2025 cash at USD 120 million and debt at USD 75 million. Those figures frame the strategy around internal resources rather than a headline financing event.

Veradigm also highlighted completed 2023 and 2024 annual filings and an ongoing 2025 audit. The company said it expected to file its 2025 Form 10-K later in 2026, linking the reporting timetable to its relisting objective.

Veradigm identified clinical and revenue cycle solutions for independent practices as core activities in its company materials. The business is also described as serving provider, payer and life sciences segments, giving the transformation plan three stated operating areas.

Investor plan centers on relisting

The numerical picture is mixed: the 2025 revenue estimate spans USD 584 million to USD 589 million, while the balance sheet figures show USD 120 million of cash against USD 75 million of debt. For investors, the key milestone is the sequence of filings and the stated relisting goal rather than a new earnings comparison.